• Asian Pacific Journal of Cancer Prevention
• /
• 제15권8호
• /
• pp.3779-3784
• /
• 2014

Aims: To study alterations of plasma lipid profiles in carcinoma cervix and to assess significance comparedwith controls in different histological grades and stages. Materials and Methods: Totals of 99 histopathologically diagnosed cases and 35 controls from a tertiary hospital situated in the southern part of India which caters the rural and semi-urban populations were considered for the study. Fasting blood samples were taken to analyze total cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL-C) and low density lipoproteins cholesterol (LDL-C), for comparison of cases, grouped according to histological grades and stages, and controls. One way ANOVA was used for multiple group comparisons and the Student's t test (unpaired) for group wise comparisons. For all tests a 'p' value of 0.05 or less was considered as significant. Results: Out of 99 cases, most (n-39) were seen in the 40-49 year age group followed by 60-69 years (n-22). Serum TG significantly differed between cases and controls but without any relation to differentiation grade. The lipid profile parameters in various grades of cervical cancer were not statistically significant. Statistically significant increase of TC and LDL-C values was observed with increase in stage of the disease. Conclusions: The study showed TG is elevated in cervical cancer, and that TC and LDL-C are proportional to the spread of cancer as it increases from stage I to stage IV. An in-depth study of molecular changes in lipid metabolism in cervical cancer patients, enzymes/genes responsible and alterations in LDL receptors is necessary to provide information to decide whether the lipid profile has any diagnostic/prognostic role in cervical cancer.

• Asian-Australasian Journal of Animal Sciences
• /
• 제14권2호
• /
• pp.237-242
• /
• 2001

Colostrum deprived, newborn pigs (N=12, $1.64{\pm}0.05kg$) were used to study the renal threshold of carnitine, and effects of emulsified medium-chain triglyceride (MCT, tri-8:0) feeding on kinetics of plasma carnitine and urinary carnitine excretion. An arterial catheter was inserted through an umbilical artery, and a bladder catheter was inserted via the urachus. Piglets were oro-gastrically gavaged with one of six carnitine levels (0, 60, 120, 180, 240, $480{\mu}mol/kg\;W^{0.75}$) with (+MCT) or without medium-chain triglycerides (-MCT) in 0.9% NaCl solution. Blood was sampled into heparinized tubes at 0, 1, 2, 4, 6, 8, 14, and 20 h after gavage, and urine was collected and pooled into 1 h or 2 h composite samples to determine free- and short-chain carnitine concentrations. Plasma from the 12 newborn piglets before gavage contained $10.6{\pm}1.2{\mu}mol/L$ free carnitine and $7.2{\pm}0.6{\mu}mol/L$ acid-soluble acyl carnitine. The renal threshold for carnitine was similar between the MCT and the +MCT group (42.6 13.1 and $46.4{\pm}2.0{\mu}mol/L$, respectively), but the correlation between plasma free carnitine and urinary excretion was altered. Plasma free carnitine linearly increased with increasing carnitine dosage (-MCT group, $R^2=0.95$, p<0.001; +MCT group, $R^2=0.91$, p<0.001), but was decreased by 50% when medium-chain triglycerides were fed. The peak in plasma free carnitine concentration was depressed by medium-chain triglycerides feeding also. Therefore, the plasma and urinary short-chain/free carnitine ratio of the +MCT group was increased by 100% and 40%, respectively (p<0.01). Feeding of medium-chain triglycerides may delay plasma carnitine elevation via altering the kinetics of absorption. Similarly, the plasma and urinary short-chain/free carnitine ratio were affected by interaction between medium-chain triglycerides and time (p<0.01). The present study suggests that an oral carnitine dose over $480{\mu}mol/kg\;W^{0.75}$ may be needed to reach the free carnitine renal threshold within a short period, especially when provided together with medium-chain triglyceride.

• 한국식품영양과학회지
• /
• 제32권6호
• /
• pp.906-912
• /
• 2003

4주간의 고지혈 유도식이를 섭취시킨 후 고지혈증 유도가 이루어진 실험 동물을 이용하여 생식 섭취로 인한 고지혈증 개선 효과를 확인하고자 하였다. 고지혈 유도가 확인된 실험 동물에게 고지혈사료에 30% 생식을 혼합한 식이를 투여하였을 경우 혈중 콜레스테롤량을 약 37% 정도 감소시킨 것으로 나타났으며, 간조직중의 콜레스테롤 역시 약 28% 감소한 것으로 나타나 생식의 섭취가 체내의 콜레스테롤 농도를 낮추어 주는 효과가 있는 것으로 확인되었다. 또한, 체내 콜레스테롤 구성에 있어서도 관상동맥 질환을 억제하는 것으로 알려진 HDL-C의 함량은 대조군에 대비하여 생식 섭취군이 약 28%정도 증가되었으며, 동맥벽에 축적되어 관상동맥질환 발병과 연관관계가 높은 것으로 알려진 LDL-C의 함량을 약 39%정도 감소시킨 것으로 나타나 체내 콜레스테롤 수치의 저하와 더불어 콜레스테롤의 구성 양상에도 이로운 점을 제공한 것으로 나타났다. 이러한 결과로부터 순환기계 질환 발병율을 나타내는 지표로 널리 이용되는 동맥경화지수와 심혈관위험지수를 산출한 결과 생식 섭취군은 대조군에 대비하여 동맥경화지수의 약 60%를 저하시켰으며, 심혈관위험지수 역시 약 56% 정도 저하시킨 것으로 나타났다. 이상의 결과를 종합하여 볼 때 생식 섭취는 체내 콜레스테롤의 농도를 저하시킴으로서 순환기계 질환의 위험도를 낮추는데 효과가 있는 것으로 생각된다.

• Asian-Australasian Journal of Animal Sciences
• /
• 제27권6호
• /
• pp.862-870
• /
• 2014

This study was conducted to investigate the effects of brown seaweed (Undaria pinnatifida) by-product and seaweed fusiforme (Hizikia fusiformis) by-product supplementation on growth performance and blood profiles including serum immunoglobulin (Ig) in broilers. Fermentation of seaweeds was conducted by Bacillus subtilis and Aspergillus oryzae. In a 5-wk feeding trial, 750 one-d-old broiler chicks were divided into 5 groups, and were assigned to the control diet or experimental diets including control+0.5% brown seaweed (BS) by-product, control+0.5% seaweed fusiforme (SF) by-product, control+0.5% fermented brown seaweed (FBS) by-product, and control+0.5% fermented seaweed fusiforme (FSF) by-product. As a consequence, body weight gain (BWG) and gain:feed of seaweed by-product groups were clearly higher, when compared to those of control diet group from d 18 to 35 and the entire experimental period (p<0.05). In mortality rate, seaweed by-product groups were significantly lower when compared to control diet group during entire experimental period (p<0.05). However, Feed Intake of experimental diets group was not different from that of the control group during the entire experimental period. Whereas, Feed Intake of fermented seaweed by-product groups was lower than that of non-fermented seaweed groups (p<0.05). Total organ weights, lipids, and glutamic oxalacetic transaminase (GOT) of all treatment groups were not different from those of control group. However, glutamic pyruvate transaminase (GPT) of all treatment groups was higher than that of control group at d 17 (p<0.05). In case of serum Igs concentration, the concentration of IgA antibody in BS, SF, FSF treatment groups was significantly higher than in control group at d 35 (p<0.01). IgA concentration in FBS supplementation groups was negligibly decreased when compared to the control group. IgM concentration in the serums of all treatment groups was significantly higher than in control group (p<0.05) and in fermented seaweed by-product groups were much higher than in non-fermented seaweed groups (p<0.05). On the other hand, IgG concentrations in all treatment groups were lower than in control group (p<0.05). Taken together, our results suggest that by-product dietary supplementation of BS, SF, FBS, and FSF in poultry may provide positive effects of growth performance and immune response.

• Journal of Pharmaceutical Investigation
• /
• 제36권1호
• /
• pp.67-73
• /
• 2006

Lornoxicam is a nonsteroidal anti-inflammatory drug that decreases prostaglandin synthesis by inhibiting cyclooxygenase. It has analgesic, antipyretic and antiinflammatory effects. The purpose of the present study was to evaluate the bioequivalence of two lornoxicam tablets, $Xefo^{\circledR}$ (Hyundai Pharmaceutical Ind. Co., Ltd.) and Lornocam (Samchundang Pharmaceutical Co., Ltd.), according to the guidelines of the Korea Food and Drug Administration (KFDA). The release of lornoxicam from the two lornoxicam formulations in vitro was tested using KP VIII Apparatus II method with various dissolution media (pH 1.2, 4.0, 6.8 buffer solution and water). Twenty eight healthy male subjects, $24.39{\pm}1.95$ years in age and $68.63{\pm}7.25$ kg in body weight, were divided into two groups and a randomized $2\;{\time}\;2$ cross-over study was employed. After a single tablet containing 4 mg as lornoxicam was orally administered, blood samples were taken at predetermined time intervals and the concentrations of lornoxicam in serum were determined using HPLC with UV detector. The dissolution profiles of two formulations were similar in all tested dissolution media. The pharmacokinetic parameters such as $AUC_t,\;C_{max}\;and\;T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_t,\;C_{max}$ and untransformed $T_{max}$. The results showed that the differences between two formulations based on the reference drug, $Xefo^{\circledR},$ were -1.56%, 2.16% and -17.12% for $AUC_t,\;C_{max}\;and\;T_{max},$ respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log 0.8 to log 1.25 (e.g., $log\;0.90{\sim}log\;1.05$ and $log\; 0.88{\sim}log\;1.17$ for $AUC_t\;and\;C_{max},$ respectively). Thus, the criteria of the KFDA bioequivalence guideline were satisfied, indicating Lornocam tablet was bioequivalent to $Xefo^{\circledR}$ tablet.

• 대한지역사회영양학회지
• /
• 제10권4호
• /
• pp.525-535
• /
• 2005

This study was conducted to investigate the effect of a 3 week low calorie diet (LCD) and a 9 week of behavior modification (BM) program on the weight loss, mineral and vitamin status in 22 obese women. The subject were healthy, obese (PIBW> $120\%$) women aged 20 - 50 Yr and not taking any medications known to influence body composition, mineral or vitamin metabolism During the LCD program, subjects were provided commercial liquid formulas with 125 kcal per pack and were instructed to have a formula for replacement of one meal and at least one regular meal per day within the range of daily 800 - 1200 kcal intake. During the BM program the subjects weekly attended the group nutrition counseling session to encourage themselves to modify their eating behavior and spontaneously restrict their energy intakes. The BM program focused on stimulus control, control of portion sizes and modification of binge eating and other adverse habits. The initial mean energy intake of subjects was 2016.9 $\pm$ 129.8 kcal ($100.8\%$ of RDA) and dropped to 1276.5 $\pm$ 435.7 kcal at the end of a 3 week of LCD program and elevated to 1762 $\pm$ 329.3 kcal at the end of a 9 week of BM program. Carbohydrate, protein and fat intakes were significantly decreased at the end of the LCD but carbohydrate was the only macro nutrient that showed significant decrease (p < 0.05) at the end of the BM program compared to baseline. Calcium and iron intakes decreased significantly (p < 0.01, respectively) with no significant changes in other micronutrients at the end of the LCD. The mean weight of the subjects decreased from 73.8 $\pm$ 8.0 kg to 69.2 $\pm$ 7.7 kg with LCD and ended up with 67.7 $\pm$ 7.1 kg after 9 weeks of BM. The 3 weeks of LCD reduced most of the anthropometric indices such as BMI, PIBW, fat weight, wast-to-hip ratio and subscapular and suprailiac skinfold thickness. The 9 weeks of behavior modification showed slight change or maintenance of each anthropometric measurements. Weight loss and decreased WHR with the diet program induced significantly decreased systolic blood pressure. SGOT, SGPT and serum insulin levels with improved serum lipid profiles. Biochemical parameters related to iron status such as hemoglobin, hematocrit were significantly decreased (p < 0.01) at the end of the LCD. But their mean values were within normal range. The mean serum 25 (OH) vitamin $D_3$ level significantly increased after whole diet program. Serum folate level significantly decreased after 12 weeks of diet program. In conclusion 3 weeks of LCD brought 4.6 kg reduction in body weight without risk of iron, zinc or vitamin D deficiency and 9 weeks of the BM was effective to maintain nutritional status with slightly more weight reduction (1.5 kg). However calcium intake and serum folate should be monitored during the LCD and BM because of increased risk of deficiencies.

• 한국유기농업학회지
• /
• 제22권2호
• /
• pp.281-291
• /
• 2014

본 연구의 목적은 황토의 식이 첨가에 의한 돼지의 성장 특성과 혈중 조성물의 변화를 규명하는 것이다. 총 153마리의 돼지(1주령 자돈 60마리 및 성돈 93마리)를 공시하였다. 자돈군은 일반사료 식이군, 0.5% 황토 + 일반사료 식이군, 1% 황토 + 일반사료 식이군으로 무작위로 3군으로 재배치하였다. 각 군간 증체량을 비교하였을 때 1% 황토가 포함된 사료를 식이한 군에서 일반사료와 0.5% 황토 + 일반사료 투여군에 비해 체중 증가가 관찰되었으나 통계적으로 유의하지는 않았다. 혈액학적 분석을 실시한 결과, 총 백혈구 수, 총 적혈구 수, 헤모글로빈 수, 혈액 중 혈구용적율, 평균 세포용적율, 평균 세포 내 헤모글로빈량, 평균 세포 내 헤모글로빈 농도, 평균 적혈구 폭, 혈소판 수치 등에서 각 군간의 유의한 차이가 없음을 확인하였다. 성돈군은 일반사료 식이군과 1% 황토 + 일반사료 식이군으로 구분하였으며, 혈청학적 분석에서 혈청 알부민의 농도는 1% 황토 + 일반사료 투여군에서 다른 군에 비하여 유의하게 증가하여 있는 것을 확인하였으나(p<0.01), 다른 지표들에서는 유의한 차이를 발견할 수 없었다. 황토가 포함된 사료를 투여한 군에서 획득한 분변의 조지방 함량은 다른 군에 비하여 유의하게 감소하는 것을 확인하였으며(p<0.001), 조단백 함량 및 조회분 함량은 유의한 차이를 보이지 않았다. 도체의 무게와 등지방 두께의 측정 결과 각 군간의 유의한 차이는 발견할 수 없었으나, 도체의 등급 판정 결과 황토를 투여한 군의 도체 등급은 비투여군에 비해 유의하게 등급이 향상된 것을 확인하였다. 이러한 결과는 황토의 식이 첨가는 돼지의 영양소 흡수를 개선시킴으로서 도체의 등급을 향상시키는 것을 확인하였다.

• 대한핵의학회지
• /
• 제28권2호
• /
• pp.172-176
• /
• 1994

심근 SPECT에 의한 심근질환의 심도 및 허혈부위를 평가하는 방법으로 정상인의 극성지도와의 비교에 의한 결손지도 평가방법이 상용화되었으나 본 연구에서는 결손부위의 범위만을 산출할 수 있었던 종래의 방법을 개선할 수 있는 관류회복정도 및 심도성적 산출 방법을 시도하여 보았다. 허혈 및 심도성적의 산출에서 부하 및 휴식기 극성지도의 차이를 3등급으로 분할하여 각 등급에 해당되는 화소의 수를 가중하므로서 관류결손부위의 면적이 반영된 허혈 및 심도성적 산출방법을 제안하고자 하였으며, 등급 및 가중치의 할당은 정상인의 잔상동맥영역별 관류분포를 반영하여 고른 등급 할당방법보다 상관도가 개선된 결과를 얻을 수 있었다.

• Childhood Kidney Diseases
• /
• 제7권1호
• /
• pp.9-15
• /
• 2003

목적 : PAN-induced nephrosis 쥐 모델에서 HMG-CoA reductase inhibitor로 작용하여 콜레스테롤을 낮추는 약제로 알려진 atorvastatin을 투여함으로써, 지질대사에 대한 효과와 지질대사의 변화가 쥐 모델의 신장 변화에 미치는 영향을 알아보고자 하였다. 대상 및 방법 : 수컷 Sprague-Dawley 흰쥐를 사용하여 대조군(I군), PAN 단독 투여군(II군), PAN과 atrovastatin 동시 투여군(III군) 3군으로 나누었으며, PAN은 체중 100 gm 당 2 mg을 첫 피하 주사한 후 1, 3, 5, 7, 9주에 반복하여 피하 주사하였으며, atorvastatin은 체중 100 gm당 5 mg을 물에 녹여 매일 경구 투여하였다. 실험 개시 후 11주에 24시간 소변과 혈액을 채취한 다음 신장을 적출 하였으며, 소변의 protein과 creatinine 그리고 혈청의 albumin, BUN, creatinine, lipid profiles를 측정하고, 신장의 형태학적 변화를 관찰하였다. 결과 : 혈청 총 콜레스테롤은 II군이 $291{\pm}173\;mg/dL$, III군이 $167{\pm}72\;mg/dL$, LDL은 II군이 $57{\pm}53\;mg/dL$, III군이 $27{\pm}12\;mg/dL$로 II군 보다 III군에서 감소하였으나 통계학적으로 유의하지는 않았다. 광학 현미경 검사상 사구체 경화의 빈도는 II군이 26.2%, III군이 13.3%로 II군보다 III군에서 적게 나타났다. 결론 : Atorvastatin을 puromycin과 같이 투여한 경우 총 콜레스테롤과 LDL을 낮추었으며 사구체 경화의 빈도도 감소시킨 것으로 보아 고지혈증이 사구체 경화성 변화에 중요한 원인 중의 하나로 생각된다.

• 대한수의학회지
• /
• 제34권2호
• /
• pp.259-266
• /
• 1994

The study was carried out to determine the pharmacokinetic parameters after intravenous(iv) and intramuscular(im) administration (10mg/kr) in healthy rabbits. The results obtained through the experiments were summarized as follows: 1. Bioassay (Bacillus cereus 11778) was evaluated very useful for the determination of oxytetracycline(OTC) in the rabbit serum and tissues, with the detection limit of $0.125{\mu}g/ml$. 2. The pharmacokinetic profiles of OTC (10mg/kg, iv) in rabbits were best described with a two compartment open model $(C=29.5e^{-4,3t}{\pm}3.6^{-0.2t})$, whereas that of OTC (10mg/kg, im) showed a one compartment curve fitting. 3. Following iv administration, a rapid distribution phase was predominant [$t_{\frac{1}{2}}({\alpha}):1.43{\pm}0.98hr$ (♂), $0.5{\pm}0.1hr$(♀)], and then more slow elimination phase ensued [$t_{\frac{1}{2}}({\beta}):4.52{\pm}0.76hr$(♂), $7.32{\pm}2.52hr$(♀)]. Other computer generated pharmacokinetic values were as follows:C1 [$67.76{\pm}18.59ml/kg/h$(♂), $76.03{\pm}22.98ml/kg/h$ (♀)] Vd [$257.74{\pm}180.47ml/kg$ (♂), $92.33{\pm}23.62$ (♀)] AUC [$25.6{\pm}4.44mgh/L$ (♂), $39.6{\pm}12.13mgh/l$ (♀)]. There were no statistical significance between both sexes for all the parameters at the confidence level of 95%. 4. After im administaration, the absorption from the injection sites was very rapid [ Ka:$0.18{\pm}0.03h^{-1}$ (♂), $0.24{\pm}0.02h^{-1}$ (♀)] followed by a monoexponential elimination fashion. The time to peak blood level (Tmax) were calculated $1.64{\pm}0.15hr$ and $1.34{\pm}0.24hr$, in the male and female, respectively. The peak levels (Cmax) at the corresponding time were $1.69{\pm}0.23{\mu}g/ml$ (♂) and $2.08{\pm}0.16{\mu}g/ml$ (♀), with no statistical differences (p>0.05).